islatravir

News

Gilead, MSD share data on once-weekly oral HIV treatment

Gilead/MSD's once-weekly oral medicine for HIV has been shown to achieve high rates of viral suppression in phase 3, setting up regulatory filings.

News

Gilead, MSD say HIV combo could be weekly, oral HIV drug

In a phase 2 trial, an antiretroviral combination developed by Gilead Sciences and MSD suppressed HIV with a single weekly oral dose, raising the hope of a new treatment option for patients

News

HIV, the AIDS virus (yellow), infecting a human cell

Gilead and MSD say weekly oral therapy controls HIV

Reducing the burden of treatment for people with HIV has been a key objective for drug developers since antiretroviral therapy (ART) first reached the market.

Gilead, MSD share data on once-weekly oral HIV treatment

Gilead, MSD say HIV combo could be weekly, oral HIV drug

Gilead and MSD say weekly oral therapy controls HIV

Novo Nordisk partners Amazon on London AI hub

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks